Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.